Therapeutic approaches to combating lipoatrophy: do they work?

被引:17
作者
Martin, A [1 ]
Mallon, PWG [1 ]
机构
[1] Univ New S Wales, Natl Ctr HIV Epidemiol & Clin Res, Darlinghurst, NSW 2010, Australia
关键词
HIV; lipodystrophy; antiretroviral therapy; body composition; hyperlipidaemia;
D O I
10.1093/jac/dki062
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Therapeutic strategies for combating HIV-associated lipodystrophy, and lipoatrophy in particular, have been a major focus of HIV clinical research. The initial impetus focused on protease inhibitor withdrawal strategies, which resulted in improved lipid profiles and insulin resistance but no change in subcutaneous or visceral adipose tissue. Nucleoside reverse transcriptase inhibitor withdrawal strategies, specifically withdrawal of thymidine analogues, have achieved greater success in the reversal of lipoatrophy. In particular, the MITOX extension study demonstrated a 35% improvement in limb fat over a 2 year period after a switch from a thymidine analogue to abacavir. However, recovery from lipoatrophy is a slow process, and limited access to and potential toxicities introduced by alternative therapies can limit switch strategies. The use of thiazolidinediones as agents to reverse lipoatrophy has, unfortunately, been shown to be ineffective, as have alternative therapeutic approaches with agents such as metformin, lipid-lowering agents and growth hormones. Although prevention of lipodystrophy may be the only definitive approach to combat this syndrome, the role of intermittent highly active antiretroviral therapy as a means of reducing the incidence, or slowing the development, of lipodystrophy is currently under evaluation.
引用
收藏
页码:612 / 615
页数:4
相关论文
共 37 条
  • [1] Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes
    Arioglu, E
    Duncan-Morin, J
    Sebring, N
    Rother, KI
    Gottlieb, N
    Lieberman, J
    Herion, D
    Kleiner, DE
    Reynolds, J
    Premkumar, A
    Sumner, AE
    Hoofnagle, J
    Reitman, ML
    Taylor, SI
    [J]. ANNALS OF INTERNAL MEDICINE, 2000, 133 (04) : 263 - 274
  • [2] Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance
    Bastard, JP
    Caron, M
    Vidal, H
    Jan, V
    Auclair, M
    Vigouroux, C
    Luboinski, J
    Laville, M
    Malachi, M
    Girard, PM
    Rozenbaum, W
    Levan, P
    Capeau, J
    [J]. LANCET, 2002, 359 (9311) : 1026 - 1031
  • [3] Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy
    Brinkman, K
    Smeitink, JA
    Romijn, JA
    Reiss, P
    [J]. LANCET, 1999, 354 (9184) : 1112 - 1115
  • [4] Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy - A randomized trial
    Carr, A
    Workman, C
    Smith, DE
    Hoy, J
    Hudson, J
    Doong, N
    Martin, A
    Amin, J
    Freund, J
    Law, M
    Cooper, DA
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 288 (02): : 207 - 215
  • [5] No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial
    Carr, A
    Workman, C
    Carey, D
    Rogers, G
    Martin, A
    Baker, D
    Wand, H
    Law, M
    Samaras, K
    Emery, S
    Cooper, DA
    [J]. LANCET, 2004, 363 (9407) : 429 - 438
  • [6] HIV protease inhibitor substitution in patients with lipodystrophy: a randomized, controlled, open-label, multicentre study
    Carr, A
    Hudson, J
    Chuah, J
    Mallal, S
    Law, M
    Hoy, J
    Doong, N
    French, M
    Smith, D
    Cooper, DA
    [J]. AIDS, 2001, 15 (14) : 1811 - 1822
  • [7] Carrieri P, 2001, J ACQ IMMUN DEF SYND, V28, P232, DOI 10.1097/00042560-200111010-00005
  • [8] Fenofibrate and rosiglitazone lower serum triglycerides with opposing effects on body weight
    Chaput, E
    Saladin, R
    Silvestre, M
    Edgar, AD
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2000, 271 (02) : 445 - 450
  • [9] Efficacy and safety of tenofovir DF vs stavuldine in combination therapy in antiretroviral-naive patients - A 3-year randomized trial
    Gallant, JE
    Staszewski, S
    Pozniak, AL
    DeJesus, E
    Suleiman, JMAH
    Miller, MD
    Coakley, DF
    Lu, B
    Toole, JJ
    Cheng, AK
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 292 (02): : 191 - 201
  • [10] Guaraldi G, 2004, ANTIVIR THER, V9, pL52